Business Context and Reporting Period
Company: Transdel Pharmaceuticals, Inc. (Note: Input metadata referenced "Harrow, Inc.", but the filing text identifies the registrant as Transdel Pharmaceuticals, Inc.)
Reporting Period: Quarterly period ended September 30, 2009 (Form 10-Q).
Business Overview: A development-stage specialty pharmaceutical company focused on non-invasive, topically delivered products using its patented Transdel™ cream formulation technology. The lead product candidate is Ketotransdel® (ketoprofen) for pain management. The company has generated no revenue since inception (July 24, 1998).
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(928,348) | $(3,777,612) | N/A |
| Operating Expenses | $929,235 | $3,787,553 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,999,154 |
| Total Assets | N/A | N/A | $2,125,309 |
| Total Liabilities | N/A | N/A | $901,249 |
| Stockholders' Equity | N/A | N/A | $1,224,060 |
| Accumulated Deficit | N/A | N/A | $(14,159,545) |
Cash Flow (Nine Months Ended Sep 30, 2009):
- Net cash used in operating activities: $(3,161,377)
- Net cash provided by financing activities: $49,500
- Net decrease in cash: $(3,111,877)
Material Changes vs. Prior Period
- Operating Loss: Net loss increased to $3.78 million for the nine months ended September 30, 2009, compared to $2.35 million in the same period of 2008.
- Research & Development (R&D): R&D expenses increased by $1.13 million (to $2.59 million) year-over-year for the nine-month period. This was primarily driven by a $1.9 million increase in costs related to the Phase 3 clinical study for Ketotransdel®, specifically investigator payments and contract research organization fees.
- Selling, General & Administrative (SG&A): SG&A expenses decreased by $122,000 (to $1.19 million) year-over-year. This decrease was due to lower amortization of stock-based compensation for investor relations firms and reduced legal fees, partially offset by increased personnel and insurance costs.
- Liquidity: Cash and cash equivalents decreased from $5.11 million at December 31, 2008, to $2.00 million at September 30, 2009.
- Liabilities: Accrued Phase 3 expenses increased significantly from $141,952 to $411,543, reflecting the progression of clinical trial costs.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that the company's continuation as a going concern is dependent on its ability to obtain additional financing. The company has incurred recurring losses and negative operating cash flows since inception.
- Clinical Outlook: The company announced top-line results for a Phase 3 trial of Ketotransdel® on October 6, 2009. However, the FDA currently requires a second Phase 3 clinical trial for final regulatory approval. The company forecasts adequate resources to fund operations through the second quarter of 2010 but will need additional capital to execute the required second Phase 3 trial.
- Financing Needs: Management intends to raise additional funds through equity or debt financing, corporate partnerships, or licensing arrangements. Failure to secure funding could force the company to cease operations.
- Cosmeceutical Program: The company entered into a licensing agreement with JH Direct, LLC for an anti-cellulite product, targeting a 2010 market introduction. This program is intended to diversify revenue streams but relies on third-party partners.
- Risks: Key risks include the uncertainty of FDA approval, the high cost of clinical trials, the potential for the stock to be classified as a "penny stock," and the lack of internal sales and marketing infrastructure.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to fund operations through Q2 2010 and the specific timeline for raising capital for the second Phase 3 trial.
- Phase 3 Results: Review the detailed data from the October 6, 2009, Phase 3 trial results and the FDA's specific requirements for the second trial.
- Accrued Liabilities: Confirm the status of the $411,543 in accrued Phase 3 expenses and the payment schedule with the contract research organization (Cato Research Ltd.).
- Dilution Risk: Assess the potential dilution from future equity financings, given the current cash position and the $14.2 million accumulated deficit.
- Stock-Based Compensation: Review the $380,329 in stock-based compensation for the nine-month period and the $749,000 in unrecognized compensation expense related to unvested options.